The early onset of peripheral neuropathy might be a robust predictor for time to treatment failure in patients with metastatic breast cancer receiving chemotherapy containing paclitaxel.

PLoS One 2017 12;12(9):e0184322. Epub 2017 Sep 12.

Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.

Background: Paclitaxel plays a central role in chemotherapy for breast cancer. Peripheral neuropathy, a well-known toxicity with paclitaxel, may be of interest in predicting the efficacy of paclitaxel therapy for patients with metastatic breast cancer. We performed a retrospective analysis assessing whether the early occurrence of peripheral neuropathy (EPN) was a predictive marker for better efficacy in patients with metastatic breast cancer receiving chemotherapy containing paclitaxel.

Patients And Methods: Between January 2000 and August 2008, we examined the records of 168 patients with metastatic breast cancer treated with paclitaxel in our hospital. EPN was defined as a symptom of Grade 2 or more during first three months of treatment. The overall response rate (ORR) and time to treatment failure (TTF) in each group were analyzed retrospectively.

Results: Of 168 patients with metastatic breast cancer who were treated with paclitaxel, EPN was documented in 101 patients (60.1%). The clinical benefit rate (CR, PR, and SD ≥ 6 months) was 72.3% in the EPN group and 49.3% in the non-EPN group (p = 0.002). The TTF of the EPN group (median 11.2 months, 95% CI: 9.5-12.9) was significantly longer than that of the non-EPN group (5.7 months, 95% CI: 4.6-6.8) (p<0.001). Multivariate analysis demonstrated that EPN (p<0.001), dose intensity of less than 70% (p<0.001), and the history of microtubule agents (p = 0.001) were the significant favorable prognostic factors for TTF.

Conclusion: The early onset of peripheral neuropathy might be a robust predictor for TTF in patients with metastatic breast cancer treated with paclitaxel.

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0184322PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595337PMC
October 2017
45 Reads

Publication Analysis

Top Keywords

breast cancer
24
metastatic breast
20
patients metastatic
20
peripheral neuropathy
12
non-epn group
8
treatment failure
8
cancer receiving
8
time treatment
8
epn group
8
treated paclitaxel
8
cancer treated
8
168 patients
8
months 95%
8
receiving chemotherapy
8
paclitaxel
6
cancer
6
breast
6
patients
6
group
5
epn
5

References

(Supplied by CrossRef)

Similar Publications